Suppr超能文献

个人生活质量作为患有或不患有自闭症谱系障碍的智力发育障碍成人问题行为抗精神病药物管理的结果指标。

Personal Quality of Life as an Outcome Measure of Antipsychotic Drug Management of Problem Behaviours in Adults with Intellectual Developmental Disorders with or Without Autism Spectrum Disorder.

作者信息

Bertelli Marco O, Bianco Annamaria, Piva Merli Micaela, Vescio Maria Stella, Rossi Michele, Buonaguro Elisabetta F

机构信息

CREA (Research and Clinical Centre), San Sebastiano Foundation, Misericordia di Firenze, 50100 Florence, Italy.

DSNP (Department of Neuro Psychiatric Sciences), University of Florence, 50100 Florence, Italy.

出版信息

Brain Sci. 2025 Mar 18;15(3):316. doi: 10.3390/brainsci15030316.

Abstract

First-generation antipsychotics (FGAs) and second-generation antipsychotics (SGAs) are frequently prescribed for the management of problem behaviours (PBs) in people with intellectual developmental disorders (IDDs) with or without autism spectrum disorder (ASD). However, the different effectiveness of these two groups of drugs has not been adequately investigated, especially in terms of person-centred outcomes, such as quality of life (QoL). The aim of the present observational study was to compare the personal QoL of two groups of people with IDDs with and without ASD, attending the same residential facility, but receiving FGAs and SGAs, respectively, for the management of PBs. Twenty-two people with IDDs (ten with ASD) receiving FGAs and twenty-three (eleven with ASD) receiving SGAs for the management of PBs were consecutively recruited. The participants underwent a complex clinical and instrumental evaluation, including the systematic psychopathological assessment for persons with intellectual and developmental disabilities-general screening (SPAIDD-G), the Wing's handicaps, behaviours, and skills schedule (HBS), the DOTES, and the BASIQ (QoL Assessment tool battery). Follow-up evaluations were carried out after 6, 12, and 18 months. The use of antipsychotics was withdrawn only in 16 cases, of which only 4 were for significant improvement. Treatment with FGAs was associated with more frequent discontinuation, a higher incidence of side effects, and a trend toward a lower efficacy on PBs than treatment with SGAs. FGAs also improved generic QoL significantly less than SGAs. The present pilot study is the first to compare FGAs and SGAs with respect to the generic QoL in people with IDDs and PBs. SGAs resulted to have a significantly greater positive impact on QoL than FGAs, despite demonstrating similar efficacy in treating PBs.

摘要

第一代抗精神病药物(FGAs)和第二代抗精神病药物(SGAs)常用于治疗伴有或不伴有自闭症谱系障碍(ASD)的智力发育障碍(IDDs)患者的问题行为(PBs)。然而,这两类药物的不同疗效尚未得到充分研究,尤其是在以患者为中心的结局方面,如生活质量(QoL)。本观察性研究的目的是比较两组分别接受FGAs和SGAs治疗PBs的IDDs患者(伴有或不伴有ASD)在同一住宿机构中的个人生活质量。连续招募了22名接受FGAs治疗PBs的IDDs患者(其中10名伴有ASD)和23名接受SGAs治疗PBs的患者(其中11名伴有ASD)。参与者接受了全面的临床和仪器评估,包括针对智力和发育障碍患者的系统精神病理学评估-一般筛查(SPAIDD-G)、温氏障碍、行为和技能量表(HBS)、DOTES以及BASIQ(生活质量评估工具组)。在6个月、12个月和18个月后进行随访评估。仅16例患者停用了抗精神病药物,其中只有4例是因为症状显著改善。与使用SGAs治疗相比,使用FGAs治疗导致停药更频繁、副作用发生率更高,且对PBs的疗效有降低趋势。FGAs对一般生活质量的改善也明显低于SGAs。本初步研究首次比较了FGAs和SGAs对IDDs和PBs患者一般生活质量的影响。尽管在治疗PBs方面显示出相似的疗效,但SGAs对生活质量的积极影响明显大于FGAs。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e09/11940582/4cf616db4de9/brainsci-15-00316-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验